GeoVax Labs, Inc.
GOVX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.21
KIRA · Stoqly’s AI analyst, in plain words
- GeoVax Labs, Inc. had $2.5M of revenue in fiscal 2025, down 37.1% on the year before. Over five years, revenue changed +6.4% a year on average.
- Its operating margin was −869.4%, down 233.5 pts: of every 100 in sales, about −869 is left after running the business.
- GeoVax Labs, Inc. lost $21.5M in fiscal 2025.
- Free cash flow was −$21.5M in fiscal 2025, −863.8% of revenue.
Market cap
—
P/E
—
Revenue
$2.5M
Net income
−$21.5M
Free cash flow
−$21.5M
Operating margin
−869.4%
GeoVax Labs, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−37.1%
No. Sales fell 37.1% last year.
Does it make a profit?
−862.4%
No. It lost money last year.
Does profit turn into cash?
−863.8%
No. It spent more cash than it brought in.
What GeoVax Labs, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 15, 2026
- Legal name
- GeoVax Labs, Inc.
- CIK
- 0000832489
GeoVax Labs, Inc. · GOVX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.4M | $0.1M | $0.0M | $4.0M | $2.5M |
| Revenue growth | −78.9% | −78.9% | −100.0% | — | −37.1% |
| Operating margin | −4,862.7% | −17,213.0% | — | −635.8% | −869.4% |
| Net income | −$18.6M | −$14.0M | −$26.0M | −$25.0M | −$21.5M |
| Net margin | −4,817.2% | −17,203.8% | — | −632.0% | −862.4% |
| Diluted EPS | −$3.04 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$11.2M | −$19.0M | −$25.2M | −$24.7M | −$21.5M |
| Capital expenditure | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$11.2M | −$19.2M | −$25.2M | −$24.7M | −$21.5M |
| FCF margin | −2,916.8% | −23,514.7% | — | −624.5% | −863.8% |
| Share count change | 340.8% | — | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $11.4M | $27.6M | $6.5M | $5.5M | $3.1M |
| Shareholders' equity | $4.4M | $26.6M | $5.8M | $5.0M | $3.8M |
| Current ratio | 2.1x | 6.1x | 2.2x | 2.6x | 2.7x |
| Interest coverage | −14,419.8x | — | — | −1,175.0x | — |
| Returns and quality | |||||
| Return on equity | −266.6% | −90.6% | −160.5% | −462.3% | −483.8% |
| Return on tangible equity | −425.8% | −52.7% | −450.6% | −495.0% | −561.2% |
| Piotroski F-score | 1 | — | — | — | — |
| Altman Z'' | −24.4 | −0.2 | −51.2 | −66.8 | −95.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
GeoVax Labs, Inc. · GOVX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.21 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0000832489). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.